Navigation Links
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
Date:12/11/2008

to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control. (vi, vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control, low incidence of hypoglycemia when used with metformin or a thiazolidinedione, and progressive weight loss. BYETTA was approved in April 2005 and has been used by approximately one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with type 2 diabetes. It is used with metformin, a sulfonylurea, or a thiazolidinedione. BYETTA is not a substitute for insulin in patients whose diabetes requires insulin treatment. BYETTA is not recommended for use in patients with severe problems digesting food or those who have severe disease of the stomach or kidney.

When BYETTA is used wit
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
2. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
3. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
4. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
7. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
8. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
9. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
10. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
(Date:9/22/2014)... Sept. 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... initiated a phase I clinical trial in patients ... safety, tolerability, and immunogenicity of INO-3106. This immunotherapy ... most aerodigestive cancers. Aerodigestive cancers affect ... and parts of the esophagus and windpipe. The ...
(Date:9/22/2014)... , Sept. 22, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... pleased to announce that TUV-SUD and The Medicinal ... (MEB) has granted its request for a ... Neutrolin was initially approved in July 2013 for ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... 2014 (HealthDay News) -- Two new prescription devices approved ... provide some relief for people with migraine headaches who ... study. One device -- the Cefaly -- is ... the Cerena -- is meant to be used when ... "Patients have been looking for alternative migraine treatments. ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
Breaking Medicine News(10 mins):Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... SETO Holdings, Inc. (Pink Sheets: SETO) announced that it signed ... (1) to issue shares of its Common Stock to acquire ... ("AHC"), a Maryland corporation which provides hearing services and retails ... Virginia, and (2) to sell all of SETO,s current businesses, ...
... how that happens may lead to ways around it, ... Temozolomide, a standard treatment for brain cancer, may boost ... more likely, a new study suggests. , The research ... City, have identified cells in brain tumors called gliomas ...
... Company Records 172% Year over Year Revenue Growth and ... Insulet,s International ExpansionBrian Roberts Appointed CFOBEDFORD, Mass., March 5 ... leader in tubing-free insulin pump technology with its OmniPod(R) ... fourth quarter and full year ended December 31, 2008. ...
... SEATTLE, March 5 Trubion Pharmaceuticals Inc. (Nasdaq: ... issue earnings results for the fourth quarter and year ... on March 12, 2009. The company,s earnings conference call ... Pacific Time, 5 p.m. Eastern Time. Both live events ...
... editors of the Harvard Health Letter , in consultation with the ... health care spending, saving society--and perhaps yourself--some money , ... Boston, MA ... will falter unless health care spending is brought under control. Moreover, even ...
... OpportunitiesHARRISBURG, Pa., March 5 Insurance Commissioner ... off from a job that offered health insurance to ... them with relief on premiums and that now is ... want to let Pennsylvanians know that additional help in ...
Cached Medicine News:Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 2Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 4Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 5Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 6Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 7Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 8Health News:Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 3Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: